GHRP and GHRH Peptides: Ipamorelin and CJC-1295
Compound Families · 7 min read · Updated on May 23, 2026
GHRP and GHRH peptides are the endogenous alternative to exogenous growth hormone: rather than injecting GH, you stimulate its release from the pituitary. The GHRP + GHRH stack co-injected is the reference protocol — it amplifies the natural pulse without disconnecting hormonal regulation. It is a well-tolerated, affordable family, suited for recovery, sleep and muscle-quality use.
This guide details the two major compounds (Ipamorelin and CJC-1295), injection timing, doses, and the place of this stack relative to exogenous HGH. For general peptide framing, see the peptides for bodybuilding guide.
The principle: amplifying the endogenous GH pulse
Growth hormone is naturally released from the pituitary in pulses — not continuously — triggered by two complementary pathways. The GHRH (Growth Hormone Releasing Hormone) pathway is the main release signal; the ghrelin/GHRP pathway reinforces and triggers an additional pulse. It is the interaction of both pathways that produces physiological pulses (notably the deep-sleep pulse and the post-workout one).
The peptides used in bodybuilding mimic these two pathways:
- GHRP (Ipamorelin, GHRP-2, GHRP-6). Ghrelin mimetics. They trigger a GH pulse by binding to the ghrelin receptor in the pituitary [5].
- GHRH (CJC-1295, Mod GRF 1-29, Sermorelin, Tesamorelin). Analogs of natural GHRH. They stimulate GH release by binding to the GHRH receptor in the pituitary.
- GHRP + GHRH co-injection. Marked synergy: the GH pulse obtained is several times higher than the sum of individual effects. This is the practical protocol.
Ipamorelin: the reference GHRP
Ipamorelin is the most selective and best tolerated GHRP. Its distinguishing trait relative to its predecessors (GHRP-6, GHRP-2) lies in its clean profile:
- No cortisol spike. GHRP-6 and GHRP-2 at high dose also stimulate cortisol and prolactin release — Ipamorelin does not at usual doses [2].
- No prolactin spike. Practical consequence: no prolactin-driven gyno risk, unlike older GHRPs.
- No major hunger effect. GHRP-6 strongly stimulates appetite (marked ghrelin effect) — Ipamorelin much less.
- Short half-life (~2 h). Means several injections per day for continuous effect, but preserves the physiological pulsatile character.
Ipamorelin dosing
| Profile | Per injection | Daily frequency |
|---|---|---|
| Peptide beginner | 200 mcg | 2× / day (fasted + bedtime) |
| Standard | 200–300 mcg | 3× / day (fasted + pre-workout + bedtime) |
| Advanced | 300 mcg | 3× / day |
Beyond 300 mcg per injection, the GH pulse no longer increases significantly (receptor saturation). No point going higher — better to multiply daily injections than unit doses.
CJC-1295: the GHRH to pick with or without DAC
CJC-1295 exists in two versions with very different behaviors:
- CJC-1295 without DAC (Mod GRF 1-29). Very short half-life (~30 min). To be injected with each GHRP dose. It is the physiological version, which amplifies the pulse at the moment the GHRP triggers it. Well-documented safety profile.
- CJC-1295 with DAC (Drug Affinity Complex). Long half-life (~8 days) thanks to binding to albumin. One injection per week is enough [3]. Downside: GH is no longer pulsatile but in a sustained plateau ('GH bleed'), which steps outside the physiological frame and may desensitize over time. Less used today in advanced protocols.
CJC-1295 dosing (without DAC)
| Profile | Per injection | Daily frequency |
|---|---|---|
| Standard | 100 mcg | Co-injected with each GHRP (2 to 3× / day) |
| Advanced | 100–200 mcg | 3× / day with GHRP |
GHRP + GHRH stack: the reference protocol
The classic stack combines 200 to 300 mcg of Ipamorelin and 100 mcg of CJC-1295 without DAC, co-injected subQ, 2 to 3 times per day. The synergy produces a GH pulse several times higher than that obtained with each compound alone. It is the base of all modern secretagogue protocols.
Injection timing: three physiological windows
- Fasted morning. Before breakfast. Leverages low blood glucose — high carbs at pulse time significantly reduce GH release (insulin antagonizes GH).
- Pre-workout. 30 to 45 minutes before the session. The GH pulse adds to the one naturally triggered by intense exercise, amplifying recovery and lipolysis.
- Bedtime. Before sleep, ideally 2 to 3 hours after the last meal. Reinforces the nocturnal GH pulse tied to deep sleep — the most important window for recovery.
Expected effects: recovery, sleep, mild lipolysis
GH secretagogues do not produce spectacular mass gains — their value is elsewhere. What is typically observed on a 12-week protocol at standard doses:
- Sleep quality. Deeper sleep, more vivid dreams, sense of more complete nocturnal recovery. Effect often perceptible in the first 2 to 4 weeks.
- Recovery between sessions. Reduced soreness, closer-together sessions better tolerated. Useful effect during intense training phases.
- Mild lipolysis. Slight fat loss notably in the abdominal area — less marked than with HGH but real over 8 to 12 weeks in a modest caloric deficit.
- Skin and joint quality. Mild anti-aging effect, joints feel more lubricated.
- IGF-1 moderately up. Typically +20 to +50% relative to baseline — much less than with HGH, but without the marked metabolic effects.
The stack is useful post-cycle (recovery), during steroid cycles (muscle-quality synergy), or standalone (anti-aging, quality of life). It is not relevant for users chasing short-term mass gain — other families answer that need better.
Side effects: limited but not nonexistent
- Transient facial flush. Face redness and warmth in the minutes following the injection, especially early in use. Benign, fades over time.
- Mild numbness / tingling in the hands. Linked to water retention, possible at high dose. Regresses on lowering.
- Mild increased hunger (modest with Ipamorelin). Residual ghrelin effect — unrelated to the massive 'hunger' effect of GHRP-6.
- Mild post-injection lethargy. May justify avoiding injection right before an activity requiring sharp alertness.
At standard doses, GH secretagogues are among the best-tolerated compounds in the field. No HPTA suppression, no aromatization, no hepatotoxicity, no particular cardio precaution at physiological doses [4]. Relevant monitoring stays glucose/HbA1c and IGF-1 for extended use (beyond 12 weeks).
Reconstitution and injection
Peptides arrive in a lyophilized vial (powder). Reconstitution with bacteriostatic water directly conditions product efficacy — tap water or non-bacteriostatic sterile water reduces post-reconstitution shelf life to a few days.
- BAC water: 2 to 4 weeks refrigerated after reconstitution.
- Insulin syringes (29 to 31 G, 0.5 ml or 1 ml) with IU graduations (1 IU = 0.01 ml) — eases precise dosing.
- SubQ injection (abdomen, thigh) with site rotation.
- Storage: lyophilized vial in freezer or refrigerator; reconstituted vial only in refrigerator.
- Standard aseptic technique: alcohol on the vial stopper, on the skin, sterile single-use syringe.
See the how to inject guide for the basics (sites, rotation, asepsis), and the gear storage guide for stock management.
Frequently asked questions
Do you need on/off cycles with this stack?
At standard doses and with CJC-1295 without DAC that preserves the pulsatile character, continuous use over several months is possible without marked desensitization. A 12-week stack cycle, followed by a 4 to 8-week break, is a prudent approach that maintains long-term pituitary sensitivity. With CJC-1295 with DAC (GH plateau), desensitization is documented from 3 to 6 months and forces breaks.
Can secretagogues and exogenous HGH be combined?
Theoretically yes but in practice value is limited: exogenous HGH inhibits the endogenous GH pulse via negative feedback, which largely cancels the secretagogue contribution. The choice is rather one or the other: secretagogues for physiological amplification and moderate cost, HGH for maximum effect and predictability, at a much higher cost.
What is the difference between Ipamorelin, GHRP-2 and GHRP-6?
Ipamorelin is the most selective — it triggers the GH pulse without significantly raising cortisol or prolactin [2]. GHRP-2 is more potent in terms of GH release but raises cortisol/prolactin at high dose. GHRP-6 is even more potent on GH but very strongly stimulates appetite (marked ghrelin effect) and raises cortisol/prolactin. For most modern protocols, Ipamorelin is the right pick: clean profile and good efficacy at usual doses.
Sources
Studies and scientific publications this guide relies on.
- Bowers CY, Momany FA, Reynolds GA, et al. (1984). On the in vitro and in vivo activity of a new synthetic hexapeptide that acts on the pituitary to specifically release growth hormone. Endocrinology. doi: 10.1210/endo-114-5-1537
Article fondateur de Bowers et Momany décrivant le premier GHRP synthétique (His-D-Trp-Ala-Trp-D-Phe-Lys-NH2, plus tard nommé GHRP-6) : libération dose-dépendante de GH par l'hypophyse in vitro et in vivo, sans relargage concomitant de LH, FSH, TSH ni prolactine — preuve de concept de la voie distincte de la GHRH naturelle.
- Raun K, Hansen BS, Johansen NL, et al. (1998). Ipamorelin, the first selective growth hormone secretagogue. European Journal of Endocrinology. doi: 10.1530/eje.0.1390552
Article original Novo Nordisk caractérisant l'Ipamorelin comme le premier GHRP réellement sélectif : libération marquée de GH à doses équivalentes au GHRP-6, mais sans élévation significative de cortisol, ACTH ni prolactine — profil de tolérance le plus propre de la famille des sécrétagogues.
- Teichman SL, Neale A, Lawrence B, et al. (2006). Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. Journal of Clinical Endocrinology & Metabolism. doi: 10.1210/jc.2005-1536
RCT chez 21 adultes sains : injection SC unique de CJC-1295 (analogue GHRH avec DAC) augmente la GH plasmatique de 2 à 10× pendant 6 jours et l'IGF-1 de 1,5 à 3× pendant 9 à 11 jours, demi-vie 5,8 à 8,1 jours, tolérance acceptable aux doses 30 et 60 µg/kg.
- Sigalos JT, Pastuszak AW (2018). The Safety and Efficacy of Growth Hormone Secretagogues. Sexual Medicine Reviews. doi: 10.1016/j.sxmr.2017.02.004
Revue clinique sur les sécrétagogues GH (sermorelin, CJC-1295, Ipamorelin, GHRP-2, MK-677) : élévation de la GH et de l'IGF-1 par stimulation hypophysaire pulsatile, profil de tolérance favorable à court terme, données long terme limitées et signal d'augmentation de l'appétit/rétention sodée modeste mais réel.
- Kojima M, Hosoda H, Date Y, et al. (1999). Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature. doi: 10.1038/45230
Article fondateur identifiant la ghréline (peptide de 28 acides aminés octanoylé sur la sérine 3) comme le ligand endogène du récepteur des sécrétagogues GH (GHS-R1a) — découvrant la voie physiologique exploitée par les GHRP synthétiques décrits 15 ans plus tôt par Bowers.
Guides liés
Molécules citées
Calculateurs utiles
Track your cycle with real data
Daily journal, 52 compounds, blood work and AI analysis — to apply what you just read and track results cycle after cycle.
Free 5-day trial — no credit card